Supernus制药 SUPN 深 沪
等待开盘 08-04 09:30:00 美东时间
35.505
+0.405
+1.15%
华盛通- 最 高35.69
- 今 开34.66
- 成交量 85.87万股
- 最 低 34.64
- 昨 收 35.10
- 总市值 19.88亿
- 52周最高 40.28
- 市盈率 静 26.90
- 换手率 1.53%
- 52周最低 29.16
- 委 比 -58.38%
- 总股本 5598.96万
- 历史最高 61.25
- 量 比 1.01
- 振 幅 2.99%
- 历史最低 4.30
- 每 手 1
- 风险率 2.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Supernus Pharmaceuticals completed its acquisition of Sage Therapeutics, enhancing its neuropsychiatric portfolio with ZURZUVAE® (zuranolone), the first FDA-approved oral treatment for postpartum depression. The deal diversifies Supernus' revenue base, adds a CNS discovery platform, and is projected to generate up to $200 million in annual cost synergies, becoming accretive in 2026. The acquisition also includes contingent value rights for Sage s...
07-31 12:44
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
Supernus Pharmaceuticals announced the expiration of the Hart-Scott-Rodino Act waiting period for its proposed acquisition of Sage Therapeutics. The $8.50 cash offer plus a contingent value right (CVR) for Sage's shares remains subject to certain conditions. The CVR includes potential payments tied to regulatory milestones and U.S. sales targets for ZURZUVAE, with total potential value up to $3.50 per share. The tender offer expires July 30, 2025...
07-28 12:25
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
Supernus Pharmaceuticals, Inc. announced it will report second-quarter 2025 financial and business results after market close on August 5, 2025. A conference call with CEO Jack Khattar and CFO Tim Dec will follow at 4:30 p.m. ET, with a live webcast available on the company’s Investor Relations website. A replay will be accessible for 60 days.
07-22 20:30
Supernus to acquire depression drugmaker Sage
Supernus Pharmaceuticals (NASDAQ:SUPN) has agreed to acquire depression drugmaker Sage Therapeutics (NASDAQ:SAGE) for a total consideration of up to $795M, or $12 per share, in an all-cash deal, the c...
06-16 19:27
Supernus Pharmaceuticals Agrees To Buy Sage Therapeutics For $8.50/Share Plus One Contingent Value Right Worth Up To $3.50 Per Share In Cash, For Total Consideration Of $12/Share
Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative
06-16 19:02
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
Supernus Pharmaceuticals has agreed to acquire Sage Therapeutics for up to $12.00 per share, valuing the deal at approximately $795 million. The transaction includes an upfront cash payment of $8.50 per share and contingent value rights worth up to $3.50 per share. Supernus expects the acquisition to strengthen its psychiatry portfolio with Sage’s ZURZUVAE, a treatment for postpartum depression, and bring significant revenue growth and cost syner...
06-16 11:00
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
Supernus Pharmaceuticals collaborates with Jay and Rosie Glazer in a new video series exploring ADHD's impact on relationships and Qelbree's role in managing symptoms. The series, launching on All About ADHD YouTube channel in May, shares Jay's ADHD journey and Rosie's supportive role, encouraging open discussions about symptoms and treatment options. Qelbree, a non-stimulant ADHD treatment for individuals 6 years and older, has helped Jay manage...
05-29 12:30
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
Supernus Pharmaceuticals received Paragraph IV Notice Letters regarding third-party submissions of ANDAs for viloxazine extended-release capsules. The company plans to enforce its intellectual property rights for Qelbree, which is covered by six U.S. patents expiring between 2029 and 2035. Supernus is a biopharmaceutical company focused on CNS disease treatments, including approved and pipeline products.
05-28 20:05
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on CNS diseases, announced that its CEO, Jack A. Khattar, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on June 4, 2025. Investors can arrange meetings with company management during the conference and access a live audio webcast or archived replay via the company's website. Supernus specializes in developing treatments for CNS disorders a...
05-28 20:05
Texas Instruments prices $1.2 billion of investment grade notes
Texas Instruments (NASDAQ:TXN) announced on Tuesday the pricing of two series of senior unsecured notes for an aggregate principal amount of $1.2 billion. The notes consist of the following: $550M of...
05-21 05:51
